Recently, a patient with huge liver cancer was admitted. The patient was only 42 years old and usually did not have any symptoms, but a physical examination revealed a 12 cm liver cancer in the right liver, the patient’s brother and younger brother both died from liver cancer, he regretted why he did not go for early examination. Liver cancer is a kind of tumor with high malignancy, and China is a large country with hepatitis B. The incidence rate of liver cancer has been high. According to the analysis of the registration information of malignant tumors in 219 registries in 2010 by the National Tumor Registry in 2013, it is estimated that in 2010, there were about 3.09 million new cases of malignant tumors and 1.96 million deaths nationwide. According to the average life expectancy of 74 years, the chance of malignant tumor in a person’s lifetime is 22%, and tumor has become a common disease. In terms of age-specific incidence rate, the incidence rate increases significantly after the age of 45, and health checkups for tumors should be emphasized from the age of 40. Lung cancer, female breast cancer, stomach cancer, liver cancer, esophageal cancer, colorectal cancer and cervical cancer are the common malignant tumors in China. Lung cancer, breast cancer, colorectal cancer and female thyroid cancer are on the rise. Lung cancer, liver cancer, stomach cancer, esophageal cancer, colorectal cancer, female breast cancer, and pancreatic cancer are the main causes of tumor death. The incidence rate of liver cancer is the fourth of all tumors, and death due to liver cancer is the second of all tumors. The key of tumor prevention and treatment strategy is “early detection, early diagnosis and early treatment”, and liver cancer is no exception, therefore, early screening for liver cancer is very important. The main causes of liver cancer in China include hepatitis virus infection, aflatoxin contamination of food, long-term alcohol abuse and blue-green algae contamination of drinking water in rural areas, as well as liver metabolic diseases, autoimmune diseases and cryptogenic liver disease or cryptogenic cirrhosis. Routine monitoring and screening indicators include serum alpha-fetoprotein (AFP) and liver ultrasonography. Screening is recommended at 6-month intervals for men older than 40 years of age or women older than 50 years of age with hepatitis B and/or C virus infection, alcoholism, co-morbid diabetes, and a family history of liver cancer. It is generally accepted that AFP is a relatively specific tumor marker for HCC and that persistent elevation of AFP is a risk factor for HCC, but about 30% of patients with liver cancer have normal AFP. The National Comprehensive Cancer Network (NCCN) recommends further liver CT or MRI for patients with elevated AFP but normal ultrasound. It is emphasized that a three-stage CT or MRI-enhanced scan of the liver is necessary to better detect the size, number, and perfusion and vascular invasion of the lesion. In particular, it should be noted that the expensive PET-CT examination is inaccurate for the diagnosis of liver cancer.